Technology evaluation: ISIS-113715, Isis.
Isis is developing ISIS-113715, an antisense inhibitor of the PTP1B gene, for the potential treatment of type 2 diabetes and obesity. ISIS-113715 is undergoing phase II clinical trials.
Liu
Gang
G
Abbott Laboratories, R4MC, AP10, 100 Abbott Park Road, Abbott Park, IL 6006-6098, USA. gang.liu@abbott.com
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009843:Oligoribonucleotides / Q000138:chemical synthesis / Q000235:genetics / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D020320:Oligoribonucleotides, Antisense / Q000138:chemical synthesis / Q000235:genetics / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010330:Patents as Topic; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases / Q000172:deficiency / Q000235:genetics*
D009843:Oligoribonucleotides; D020320:Oligoribonucleotides, Antisense; C496122:ISIS-113715; C516607:PTPN1 protein, human; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases; C516609:Ptpn1 protein, mouse